IGC Pharma, Inc., a Maryland corporation, was established on April 29, 2005. The company is a clinical-stage biotechnology company focused on the development of novel therapies for neuropsychiatric and neurodegenerative diseases, primarily for Alzheimer's disease. Its lead drug candidate, IGC-AD 1, is in Phase 2 trials for Alzheimer's dementia agitation, while an artificial intelligence data platform for research support is also being developed.
